Market Place
Sourcing Support
Iovance Biotherapeutics Q3 & YTD 2024 Results & Updates
07 Nov 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Host Q3 & YTD 2024 Results Call on Nov 7
31 Oct 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at Upcoming Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
16 Aug 2024 //
GLOBENEWSWIRE
Iovance Reports Q2 And H1 2024 Results And Updates
08 Aug 2024 //
GLOBENEWSWIRE
Iovance To Host Q2 And H1 2024 Results Call On August 8, 2024
29 Jul 2024 //
GLOBENEWSWIRE
Iovance Reports Inducement Grants Under NASDAQ Rule 5635(C)(4)
19 Jul 2024 //
GLOBENEWSWIRE
Iovance Submits Marketing Application To EMA For Lifileucel In Advanced Melanoma
28 Jun 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics Inducement Grants NASDAQ Rule 5635(c)(4)
21 Jun 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at Upcoming Conferences and Events
24 May 2024 //
GLOBENEWSWIRE
BMS` triplet, Iovance`s Amtagvi-Keytruda target melanoma
24 May 2024 //
FIERCE PHARMA
Iovance Frontline Melanoma Data: To Be Presented At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Iovance Reports Inducement Grants Under Nasdaq 5635(c)(4)
17 May 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics Q1 2024 Financials And Corporate Update
09 May 2024 //
GLOBENEWSWIRE
Iovance Q1 2024 Results Call, Webcast On May 9
01 May 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at Upcoming Conferences
30 Apr 2024 //
GLOBENEWSWIRE
Iovance to Present Clinical & Translational Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
Iovance Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19 Apr 2024 //
GLOBENEWSWIRE
Iovance Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22 Mar 2024 //
GLOBENEWSWIRE
Iovance Bio Announces FDA has Lifted Clinical Hold on the IOV-LUN-202
04 Mar 2024 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at Upcoming Conferences
01 Mar 2024 //
GLOBENEWSWIRE
Iovance’s Amtagvi sees ‘healthy demand’ after US approval
29 Feb 2024 //
ENDPTS
Iovance Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
Iovance Bio to Host Fourth Quarter and Full-Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Iovance Announces Pricing of $211 Million Underwritten Offering of Common Stock
20 Feb 2024 //
GLOBENEWSWIRE
WuXi AppTec subsidiary to manufacture Iovance’s solid tumor TIL therapy in US
20 Feb 2024 //
ENDPTS
US FDA grants accelerated approval for Iovance`s skin cancer cell therapy
17 Feb 2024 //
REUTERS
Iovance to Host Conference Call and Webcast on Friday, February 16, 2024
16 Feb 2024 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
16 Feb 2024 //
GLOBENEWSWIRE
Why Iovance Biotherapeutics Stock Is Skyrocketing Today
01 Feb 2024 //
FOOL
Iovance Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
19 Jan 2024 //
GLOBENEWSWIRE
Iovance Plummets as FDA Halts Cancer Drug Trial After Death
28 Dec 2023 //
YAHOO FINANCE
Iovance Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22 Dec 2023 //
GLOBENEWSWIRE
Iovance Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
17 Nov 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics Reports Third Quarter Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Iovance Bio to Present Clinical and Pre-Clinical Data for TIL Therapies
31 Oct 2023 //
GLOBENEWSWIRE
Iovance to Host Third Quarter and Year-to-Date 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Iovance Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
20 Oct 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics Announces Clinical Data for Lifileucel at ESMO
16 Oct 2023 //
GLOBENEWSWIRE
Iovance Bio to Present Clinical and Pre-Clinical Data for TIL Therapies
27 Sep 2023 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22 Sep 2023 //
GLOBENEWSWIRE
U.S. Food and Drug Administration Updates PDUFA Action Date for Lifileucel
14 Sep 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
07 Sep 2023 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
18 Aug 2023 //
GLOBENEWSWIRE
Iovance Bio Reports Second Quarter and First Half 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present Clinical Data for TIL Therapy at IASLC
25 Jul 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference
24 Jul 2023 //
GLOBENEWSWIRE
Iovance Bio Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
21 Jul 2023 //
GLOBENEWSWIRE
Iovance Biot Announces Closing of $172.5 Million Common Stock Public Offering
13 Jul 2023 //
GLOBENEWSWIRE
Iovance Bio Announces Regulatory and Clinical Updates for TIL Therapy
10 Jul 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
10 Jul 2023 //
GLOBENEWSWIRE
Iovance Announces Pricing of Its Public Offering of $150 Million of Common Stock
10 Jul 2023 //
GLOBENEWSWIRE
Iovance gets FDA ok for accelerated review of lung cancer drug
10 Jul 2023 //
FIERCE BIOTECH
Iovance to Host Virtual Roundtable with Key Opinion Leaders
20 Jun 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics Announces First Patient Randomized in Ph3 TILVANCE-301
15 Jun 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
09 Jun 2023 //
GLOBENEWSWIRE
Iovance Announces U.S. FDA Acceptance of the BLA of Lifileucel
26 May 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics Reports1Q 2023 FYR and Corporate Updates
09 May 2023 //
GLOBENEWSWIRE
Iovance Biotherapeutics to Host 1Q 2023 FYR Conference Call
02 May 2023 //
GLOBENEWSWIRE
Iovance Completes BLA Submission for Lifileucel in Advanced Melanoma
24 Mar 2023 //
GLOBENEWSWIRE
